Clinical Trial Update: Expanded Access of Cabozantinib in Medullary Thyroid Cancer

View source ↗

Summary

The document reports expanded access for cabozantinib in medullary thyroid cancer and indicates marketing approval status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Cancer

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Exelixis | Conditions: Medullary Thyroid Cancer | Status: APPROVED_FOR_MARKETING